SARS‐CoV‐2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad
- 8 May 2020
- journal article
- editorial
- Published by Wiley in Annals of Neurology
- Vol. 87 (6) , 794-797
Abstract
A major concern during the current severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic1 is the use of immunosuppressive therapies for the treatment of multiple sclerosis (MS) due to an increased risk of contracting SARS‐CoV‐2 and more severe disease. The Society of Italian Neurologists (SIN) and the Association of British Neurologists (ABN) MS and Neuroimmunology Advisory Group published guidance for the use of current disease modifying treatments (DMTs) in MS (Table 1)2. However, taking into account, less conservative viewpoints3, the emerging knowledge of the biology of SARS‐CoV‐2, and in particular the role of the immune mechanisms contributing to the disease, we propose modification of these guidelines since it is not clear that immunosuppression is indeed detrimental in people with MS infected with SARS‐CoV‐2. We are thus proposing a more nuanced approach and that the categories of DMTs should be modified based on scientific principles and the biology of severe COVID‐19 (Table 2).Keywords
This publication has 15 references indexed in Scilit:
- COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?Multiple Sclerosis and Related Disorders, 2020
- Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recoverPediatric Allergy and Immunology, 2020
- Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patientsEmerging Microbes & Infections, 2020
- Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatmentMultiple Sclerosis and Related Disorders, 2017
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of AlemtuzumabJAMA Neurology, 2017
- Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculationJournal of Neuroinflammation, 2017
- Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple SclerosisEBioMedicine, 2017
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisNew England Journal of Medicine, 2017
- Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisNew England Journal of Medicine, 2017
- Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factorsBiochemical Journal, 2005